MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Optimal treatment for advanced endometrial cancer with extra-uterine metastasis remains elusive.
• Understanding the genomic landscape is key to identifying novel therapeutic targets.

Purpose of the Study:

• To analyze the genomic profiles of advanced endometrial cancer patients.
• To identify genomic aberrations linked to clinical outcomes.
• To explore potential therapeutic targets for improved patient survival.

Main Methods:

• Integrated clinical and genomic data from 81 stage III/IV endometrial cancer patients.
• Utilized Cox proportional hazard regression to correlate genomic aberrations with outcomes.
• Validated findings through in vitro and in vivo experiments.

Main Results:

• Mutations in MET, U2AF1, BCL9, PPP2R1A, IDH2, CBL, BTK, and CHEK2 correlated with poor clinical outcomes.
• MET mutations (30%) were associated with significantly poorer overall survival (HR 2.606).
• Concurrent MET and KRAS mutations indicated the worst outcomes; MET N375S mutation confers cisplatin resistance and is prevalent in Eastern Asian populations.

Conclusions:

• Specific gene mutations, especially in MET, are significant predictors of poor prognosis in advanced endometrial cancer.
• MET mutation type influences tumor growth and sensitivity to therapies like cisplatin and tyrosine kinase inhibitors.
• Ethnic differences in endometrial cancer biology, exemplified by the MET N375S variant, necessitate tailored treatment recommendations and clinical trial designs.